These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 22348277)

  • 1. A Bayesian approach to improved estimation of causal effect predictiveness for a principal surrogate endpoint.
    Zigler CM; Belin TR
    Biometrics; 2012 Sep; 68(3):922-32. PubMed ID: 22348277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating candidate principal surrogate endpoints.
    Gilbert PB; Hudgens MG
    Biometrics; 2008 Dec; 64(4):1146-54. PubMed ID: 18363776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and estimation for evaluating principal surrogate markers in vaccine trials.
    Huang Y; Gilbert PB; Wolfson J
    Biometrics; 2013 Jun; 69(2):301-9. PubMed ID: 23409839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solutions for surrogacy validation with longitudinal outcomes for a gene therapy.
    Roberts EK; Elliott MR; Taylor JMG
    Biometrics; 2023 Sep; 79(3):1840-1852. PubMed ID: 35833874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating surrogate markers of clinical outcome when measured with error.
    Dafni UG; Tsiatis AA
    Biometrics; 1998 Dec; 54(4):1445-62. PubMed ID: 9883544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surrogacy assessment using principal stratification with multivariate normal and Gaussian copula models.
    Taylor JM; Conlon AS; Elliott MR
    Clin Trials; 2015 Aug; 12(4):317-22. PubMed ID: 25490988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incorporating baseline covariates to validate surrogate endpoints with a constant biomarker under control arm.
    Roberts EK; Elliott MR; Taylor JMG
    Stat Med; 2021 Dec; 40(29):6605-6618. PubMed ID: 34528260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surrogacy assessment using principal stratification when surrogate and outcome measures are multivariate normal.
    Conlon AS; Taylor JM; Elliott MR
    Biostatistics; 2014 Apr; 15(2):266-83. PubMed ID: 24285772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating a surrogate endpoint at three levels, with application to vaccine development.
    Gilbert PB; Qin L; Self SG
    Stat Med; 2008 Oct; 27(23):4758-78. PubMed ID: 17979212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Bayesian approach to estimating causal vaccine effects on binary post-infection outcomes.
    Zhou J; Chu H; Hudgens MG; Halloran ME
    Stat Med; 2016 Jan; 35(1):53-64. PubMed ID: 26194767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing Bayesian hierarchical meta-regression methods and evaluating the influence of priors for evaluations of surrogate endpoints on heterogeneous collections of clinical trials.
    Collier W; Haaland B; Inker LA; Heerspink HJL; Greene T
    BMC Med Res Methodol; 2024 Feb; 24(1):39. PubMed ID: 38365599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian estimation of the proportion of treatment effect captured by a surrogate marker.
    Cowles MK
    Stat Med; 2002 Mar; 21(6):811-34. PubMed ID: 11870819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis for the evaluation of potential surrogate markers.
    Daniels MJ; Hughes MD
    Stat Med; 1997 Sep; 16(17):1965-82. PubMed ID: 9304767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing biomarkers as trial level general surrogates.
    Gabriel EE; Daniels MJ; Halloran ME
    Biometrics; 2016 Dec; 72(4):1046-1054. PubMed ID: 27038302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A semiparametric Bayesian approach to the random effects model.
    Kleinman KP; Ibrahim JG
    Biometrics; 1998 Sep; 54(3):921-38. PubMed ID: 9750242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accommodating missingness when assessing surrogacy via principal stratification.
    Elliott MR; Li Y; Taylor JM
    Clin Trials; 2013; 10(3):363-77. PubMed ID: 23553326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A bayesian approach to surrogacy assessment using principal stratification in clinical trials.
    Li Y; Taylor JM; Elliott MR
    Biometrics; 2010 Jun; 66(2):523-31. PubMed ID: 19673864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Bayesian prediction model between a biomarker and the clinical endpoint for dichotomous variables.
    Jiang Z; Song Y; Shou Q; Xia J; Wang W
    Trials; 2014 Dec; 15():500. PubMed ID: 25528466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials.
    Gilbert PB; Bosch RJ; Hudgens MG
    Biometrics; 2003 Sep; 59(3):531-41. PubMed ID: 14601754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Commentary on "Principal stratification - a goal or a tool?" by Judea Pearl.
    Gilbert PB; Hudgens MG; Wolfson J
    Int J Biostat; 2011; 7(1):Article 36. PubMed ID: 22049267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.